Characterization and implications of host‐cell protein aggregates in biopharmaceutical processing
Biotechnology and Bioengineering · 2023-04 · 120 (4) · 1068-1080
DOI: 10.1002/bit.28325 ↗At a glance
Journal article in Biotechnology and Bioengineering, 2023-04. Written by Young Hoon Oh and 13 co-authors. Institution: Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, Delaware, USA. Major MEDLINE topics: Protein Aggregates, Biological Products. Cited 25 times so far (Crossref); 47 references. Funded by: National Institute for Innovation in Manufacturing Biopharmaceuticals.
Abstract (original language)
In the production of biopharmaceuticals such as monoclonal antibodies (mAbs) and vaccines, the residual amounts of host‐cell proteins (HCPs) are among the critical quality attributes. In addition to overall HCP levels, individual HCPs may elude purification, potentially causing issues in product stability or patient safety. Such HCP persistence has been attributed mainly to biophysical interactions between individual HCPs and the product, resin media, or residual chromatin particles. Based on measurements on process streams from seven mAb processes, we have found that HCPs in aggregates, not necessarily chromatin‐derived, may play a significant role in the persistence of many HCPs. Such aggregates may also hinder accurate detection of HCPs using existing proteomics methods. The findings also highlight that certain HCPs may be difficult to remove because of their functional complementarity to the product; specifically, chaperones and other proteins involved in the unfolded protein response (UPR) are disproportionately present in the aggregates. The methods and findings described here expand our understanding of the origins and potential behavior of HCPs in cell‐based biopharmaceutical processes and may be instrumental in improving existing techniques for HCP detection and clearance.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, Delaware, USA.
- Purification Process Development, Genentech, Inc., South San Francisco, California, USA.
- Analytical Research and Development, Merck & Co., Inc., Kenilworth, New Jersey, USA.
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey, USA.
- Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, New York, USA.
- Department of Chemical and Biomolecular Engineering, North Carolina State University, Raleigh, North Carolina, USA.
ORCID profiles: Kelvin H Lee, Steven M Cramer, Abraham M Lenhoff
Funding
- National Institute for Innovation in Manufacturing Biopharmaceuticals
Cite
APA
Oh, Y. H., Becker, M. L., Mendola, K. M., Choe, L. H., Min, L., Lee, K. H., Yigzaw, Y., Seay, A., Bill, J., Li, X., Roush, D. J., Cramer, S. M., Menegatti, S., & Lenhoff, A. M. (2023). Characterization and implications of host‐cell protein aggregates in biopharmaceutical processing. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.28325
Vancouver
Oh YH, Becker ML, Mendola KM, Choe LH, Min L, Lee KH, et al. Characterization and implications of host‐cell protein aggregates in biopharmaceutical processing. Biotechnology and Bioengineering. 2023. doi:10.1002/bit.28325
BibTeX
@article{Oh2023,
author = {Oh, Young Hoon and Becker, Matthew L and Mendola, Kerri M and Choe, Leila H and Min, Lie and Lee, Kelvin H and Yigzaw, Yinges and Seay, Alexander and Bill, Jerome and Li, Xuanwen and Roush, David J and Cramer, Steven M and Menegatti, Stefano and Lenhoff, Abraham M},
title = {Characterization and implications of host‐cell protein aggregates in biopharmaceutical processing},
journal = {Biotechnology and Bioengineering},
year = {2023},
doi = {10.1002/bit.28325}
}
EUVIMED